ECSP23095307A - Agonista del receptor de glp-1 y composición y uso del mismo - Google Patents

Agonista del receptor de glp-1 y composición y uso del mismo

Info

Publication number
ECSP23095307A
ECSP23095307A ECSENADI202395307A ECDI202395307A ECSP23095307A EC SP23095307 A ECSP23095307 A EC SP23095307A EC SENADI202395307 A ECSENADI202395307 A EC SENADI202395307A EC DI202395307 A ECDI202395307 A EC DI202395307A EC SP23095307 A ECSP23095307 A EC SP23095307A
Authority
EC
Ecuador
Prior art keywords
glp
composition
receptor agonist
receptor
disorders
Prior art date
Application number
ECSENADI202395307A
Other languages
English (en)
Inventor
Zhe Wang
Wenqiang Zhai
Liubin Guo
Zhimin Zhang
Qian Wang
Hao Pan
Original Assignee
Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Publication of ECSP23095307A publication Critical patent/ECSP23095307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto agonista del receptor de GLP-1 y una composición y uso del mismo. El compuesto puede utilizarse para tratar o prevenir enfermedades o trastornos mediados por el receptor de GLP-1 y enfermedades o trastornos relacionados. (II)
ECSENADI202395307A 2021-06-24 2023-12-19 Agonista del receptor de glp-1 y composición y uso del mismo ECSP23095307A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110702643 2021-06-24

Publications (1)

Publication Number Publication Date
ECSP23095307A true ECSP23095307A (es) 2024-01-31

Family

ID=84544137

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202395307A ECSP23095307A (es) 2021-06-24 2023-12-19 Agonista del receptor de glp-1 y composición y uso del mismo

Country Status (18)

Country Link
US (2) US11981666B2 (es)
EP (1) EP4361145A4 (es)
JP (1) JP2024523525A (es)
KR (1) KR20240024910A (es)
CN (2) CN117098758A (es)
AU (1) AU2022300055A1 (es)
CA (1) CA3219984A1 (es)
CL (1) CL2023003794A1 (es)
CO (1) CO2023017726A2 (es)
CR (1) CR20230611A (es)
DO (1) DOP2023000275A (es)
EC (1) ECSP23095307A (es)
IL (1) IL309235A (es)
MX (1) MX2023014985A (es)
PE (1) PE20241794A1 (es)
TW (1) TW202317553A (es)
WO (1) WO2022268152A1 (es)
ZA (1) ZA202400786B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
LT4271672T (lt) 2021-04-21 2026-03-10 Gilead Sciences, Inc. Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
KR20240053617A (ko) 2021-08-30 2024-04-24 민드랭크 에이아이 리미티드 Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
AU2023394509A1 (en) * 2022-12-13 2025-07-10 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof
JP2026501161A (ja) * 2022-12-13 2026-01-14 杭州中美華東製薬有限公司 Ｇｌｐ－１受容体作動薬の新規結晶形、その製造方法、その医薬組成物およびその使用
CN118496200A (zh) * 2023-02-14 2024-08-16 成都康弘药业集团股份有限公司 吲唑啉酮类化合物及其制备方法和用途
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN121866253A (zh) 2023-07-04 2026-04-14 杭州中美华东制药有限公司 一种glp1r激动剂及其中间体的制备方法
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
TW202612693A (zh) * 2024-06-05 2026-04-01 大陸商杭州中美華東製藥有限公司 Glp-1受體激動劑的口服藥物組合物及其製備方法
WO2026049510A1 (en) * 2024-08-28 2026-03-05 Yuhan Corporation Thienoimidazole compounds having glp-1 receptor agonist activity, methods for preparing same, and medical uses thereof
TW202615019A (zh) * 2024-09-05 2026-04-16 大陸商杭州中美華東製藥有限公司 Glp-1r激動劑與恩格列淨的藥物組合物及用途
CN119837849B (zh) * 2025-02-10 2025-06-13 中国科学院北京基因组研究所(国家生物信息中心) 蜡菊素在制备缓解和治疗受试者细胞红系分化障碍的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
US10723699B2 (en) 2015-11-04 2020-07-28 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2018109607A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
KR101910586B1 (ko) 2017-03-03 2018-10-23 한국화학연구원 헤테로아릴이 치환된 2-페닐이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 GLP-1 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
WO2021018023A1 (zh) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CR20220178A (es) * 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
CN115697999A (zh) * 2020-02-13 2023-02-03 加舒布鲁姆生物公司 杂环glp-1激动剂
CN115515956B (zh) * 2020-09-29 2024-06-25 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
EP4247804A1 (en) * 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4271674B9 (en) * 2021-04-21 2026-03-11 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds

Also Published As

Publication number Publication date
PE20241794A1 (es) 2024-09-06
WO2022268152A1 (zh) 2022-12-29
TW202317553A (zh) 2023-05-01
CN117362283A (zh) 2024-01-09
JP2024523525A (ja) 2024-06-28
CN117098758A (zh) 2023-11-21
EP4361145A1 (en) 2024-05-01
ZA202400786B (en) 2024-10-30
CA3219984A1 (en) 2022-12-29
CL2023003794A1 (es) 2024-05-24
MX2023014985A (es) 2024-02-14
DOP2023000275A (es) 2024-02-15
IL309235A (en) 2024-02-01
KR20240024910A (ko) 2024-02-26
CO2023017726A2 (es) 2024-02-15
CR20230611A (es) 2024-02-19
US11981666B2 (en) 2024-05-14
CN117362283B (zh) 2024-07-09
US20240360110A1 (en) 2024-10-31
EP4361145A4 (en) 2025-05-21
AU2022300055A1 (en) 2024-01-18
US20240116906A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
CL2023003794A1 (es) Agonista del receptor de glp-1 y composición y uso del mismo
UY38958A (es) Agonista del receptor glp-1 y uso de este
MX2024003236A (es) Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
MX2021007576A (es) Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8).
CO2025011012A2 (es) Agonistas heterocíclicos de glp-1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
UY37098A (es) Moduladores de ror-gamma
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
MX2018008050A (es) Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada.
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
MX2021005725A (es) Tratamiento de la obesidad y sus complicaciones.
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
JOP20200265A1 (ar) متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 (glp-1) واستخداماتها
CL2019003325A1 (es) Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca.
DOP2019000183A (es) Moduladores del receptor de estrógeno
CL2008002096A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor vanilloide vr-1 y un antiinflamatorio no esteroidal o una sal o solvato de cualquiera o de ambos compuestos; composicion farmaceutica que comprende dicha combinacio; y su uso de la combinacion para tratar un trastorno mediado por ek receptor vainilloide vr1.
MX2021014357A (es) Metodos y formulaciones para tratar trastornos de la vision.